Mylan Talks Up Prospects For Becoming Leader In Generic Injectables
This article was originally published in The Pink Sheet Daily
The generic drug maker has set ambitious price targets for its stock over the next five years based on recently acquired assets and some risky generic drug launches. Analysts are concerned the company is putting too much faith in high-risk projects.
You may also be interested in...
FDA is pushing forward with its review of Mylan’s ANDA for generic Advair, according to the company, which is gaining confidence that the application could receive a first round approval. The experience for that application, which has a generic drug user fee, is a clear contrast to the firm's experience with its pre-GDUFA Copaxone filing.
Federal Circuit finds claims covering Copaxone’s latest expiring patent are invalid; Mylan says it plans to launch its generic of the MS drug in May 2014.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.